Results 111 to 120 of about 27,341 (230)
, 2012 Sahar Naderi,1 JoAnne M Foody21Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USAAbstract: The majority of chronic kidney disease ...
Foody JM, Naderi S
core
Ezetimibe and vascular endothelial function. [PDF]
, 2011 Hypercholesterolemia is a major risk factor for cardiovascular diseases that has been managed mostly with 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors (statins) that suppress de novo cholesterol synthesis in the liver.
Maemura, Koji, Ikeda, Satoshi
core +2 more sources
FABRICATION AND CHARACTERIZATION OF EZETIMIBE SOLID DISPERSION FOR SOLUBILITY ENHANCEMENT [PDF]
, 2017 Objective: The objective of the present study was to formulate solid dispersions (SD) of Ezetimibe to improve the solubility and dissolution rate to facilitate faster onset of action.
E, Achadu A, Jajere, Usman Mohammed
core +1 more source
Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G
Diabetes, Obesity and Metabolism, EarlyView.
Michelantonio De Fano +6 more
wiley +1 more source
Advanced Science, Volume 13, Issue 35, 24 June 2026.Phospholipid transfer protein(PLTP) plays a critical role in forming a complex with kinase A (AURKA) and P65. This interaction facilitates phosphorylation of P65 at Ser536, leading to the activation of the NF‐κB signaling pathway. Ultimately, this leads to the upregulation of downstream cytokines, including IL‐6, IL‐8, and CSF‐1, which promotes M2 ...
Xinyue Liang +14 more
wiley +1 more source
Ezetimibe therapy: mechanism of action and clinical update
, 2012 Binh An P Phan,1 Thomas D Dayspring,2 Peter P Toth31Division of Cardiology, Loyola University Medical Center, Maywood, IL, USA; 2Foundation for Health Improvement and Technology, Wayne, NJ, USA; 3CGH Medical Center, Sterling, IL, USAAbstract: The ...
Toth PP, Dayspring TD, Phan BAP
core
JAMA cardiology, 2019 Importance Limited evidence is available regarding the benefit and hazard of higher-intensity treatment to lower lipid levels among patients 75 years or older.
R. Bach +8 more
semanticscholar +1 more source
Catheterization and Cardiovascular Interventions, Volume 107, Issue 7, Page 2293-2303, June 1, 2026.ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu +9 more
wiley +1 more source
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
, 2002 ObjectivesThe purpose of this study was to assess the efficacy and safety of ezetimibe administered with simvastatin in patients with primary hypercholesterolemia.BackgroundDespite the availability of statins, many patients do not achieve lipid targets ...
Suresh, Ramachandran +8 more
core +1 more source
Clinical Case Reports, Volume 14, Issue 6, June 2026.ABSTRACT Severe coronary calcification is a common challenge in percutaneous coronary intervention, often resulting in suboptimal stent expansion. Intravascular lithotripsy (IVL) employs acoustic pressure waves to fracture calcified plaques and increase procedural success.
Liang‐cai Guo +3 more
wiley +1 more source